Affinity Asset Advisors LLC Sells 289,414 Shares of Savara Inc (NASDAQ:SVRA)

Affinity Asset Advisors LLC trimmed its position in Savara Inc (NASDAQ:SVRA - Free Report) by 41.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 410,586 shares of the company's stock after selling 289,414 shares during the period. Affinity Asset Advisors LLC owned approximately 0.24% of Savara worth $1,260,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of Savara by 4.6% in the fourth quarter. Vanguard Group Inc. now owns 8,309,970 shares of the company's stock valued at $25,512,000 after purchasing an additional 365,959 shares during the last quarter. State Street Corp lifted its holdings in Savara by 15.7% during the third quarter. State Street Corp now owns 4,138,276 shares of the company's stock valued at $17,546,000 after purchasing an additional 560,242 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Savara by 2.1% in the fourth quarter. Geode Capital Management LLC now owns 2,784,037 shares of the company's stock worth $8,549,000 after purchasing an additional 57,187 shares in the last quarter. Rosalind Advisors Inc. purchased a new stake in Savara during the 4th quarter worth about $8,151,000. Finally, Emerald Advisers LLC purchased a new position in Savara during the 4th quarter valued at about $7,161,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Savara Price Performance

NASDAQ SVRA traded up $0.08 during trading hours on Friday, reaching $3.01. 465,408 shares of the stock traded hands, compared to its average volume of 1,317,363. The stock has a 50 day simple moving average of $2.74 and a two-hundred day simple moving average of $3.09. The company has a market cap of $519.63 million, a price-to-earnings ratio of -7.00 and a beta of 0.52. Savara Inc has a 1 year low of $2.26 and a 1 year high of $5.31. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70.

Savara (NASDAQ:SVRA - Get Free Report) last released its earnings results on Thursday, March 27th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The company had revenue of $0.27 million for the quarter. On average, analysts predict that Savara Inc will post -0.45 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a "buy" rating and issued a $6.00 price objective on shares of Savara in a research report on Friday, March 28th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $8.83.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.